BRPI1010937A2 - composto, uso de um composto, e, método para tratar câncer - Google Patents
composto, uso de um composto, e, método para tratar câncerInfo
- Publication number
- BRPI1010937A2 BRPI1010937A2 BRPI1010937A BRPI1010937A BRPI1010937A2 BR PI1010937 A2 BRPI1010937 A2 BR PI1010937A2 BR PI1010937 A BRPI1010937 A BR PI1010937A BR PI1010937 A BRPI1010937 A BR PI1010937A BR PI1010937 A2 BRPI1010937 A2 BR PI1010937A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treating cancer
- cancer
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18023809P | 2009-05-21 | 2009-05-21 | |
| PCT/GB2010/050825 WO2010133885A1 (en) | 2009-05-21 | 2010-05-20 | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1010937A2 true BRPI1010937A2 (pt) | 2019-09-24 |
Family
ID=42315702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010937A BRPI1010937A2 (pt) | 2009-05-21 | 2010-05-20 | composto, uso de um composto, e, método para tratar câncer |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20120122867A1 (pt) |
| EP (1) | EP2432768B1 (pt) |
| JP (1) | JP5913093B2 (pt) |
| KR (1) | KR20120030436A (pt) |
| CN (1) | CN102482233A (pt) |
| AR (1) | AR078045A1 (pt) |
| AU (1) | AU2010250923A1 (pt) |
| BR (1) | BRPI1010937A2 (pt) |
| CA (1) | CA2760766A1 (pt) |
| CL (1) | CL2011002942A1 (pt) |
| CO (1) | CO6470845A2 (pt) |
| CR (1) | CR20110610A (pt) |
| CU (1) | CU20110212A7 (pt) |
| DO (1) | DOP2011000361A (pt) |
| EA (1) | EA201101650A1 (pt) |
| EC (1) | ECSP11011470A (pt) |
| IL (1) | IL216283A0 (pt) |
| MX (1) | MX2011012337A (pt) |
| SG (1) | SG175796A1 (pt) |
| TW (1) | TW201100083A (pt) |
| UY (1) | UY32648A (pt) |
| WO (1) | WO2010133885A1 (pt) |
| ZA (1) | ZA201109384B (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102666541B (zh) | 2009-10-22 | 2015-11-25 | 吉里德科学公司 | 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物 |
| WO2012066336A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| WO2012066335A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
| EP2640716A1 (en) * | 2010-11-19 | 2013-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amide compounds and their use in the treatment of disease |
| WO2012067269A1 (en) * | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
| ES2575688T3 (es) | 2010-12-16 | 2016-06-30 | Sumitomo Dainippon Pharma Co., Ltd. | Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia |
| JP5978226B2 (ja) | 2010-12-17 | 2016-08-24 | 大日本住友製薬株式会社 | プリン誘導体 |
| KR20140030132A (ko) | 2011-01-10 | 2014-03-11 | 클리브랜드 바이오랩스, 아이엔씨. | 암을 치료하기 위한 톨-유사 수용체 효능제의 용도 |
| KR101946499B1 (ko) * | 2011-04-08 | 2019-02-11 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 치료를 위한 피리미딘 유도체 |
| EP2776439B1 (en) | 2011-11-09 | 2018-07-04 | Janssen Sciences Ireland UC | Purine derivatives for the treatment of viral infections |
| FR2985256B1 (fr) * | 2011-12-30 | 2016-03-04 | Pitty Marc Henry | Derives piperazinyles pour le traitement de cancers |
| EA039373B1 (ru) * | 2012-02-08 | 2022-01-19 | Янссен Сайенсиз Айрлэнд Юси | Производные пиперидино-пиримидина для лечения вирусных инфекций |
| AU2013261267B2 (en) | 2012-05-18 | 2017-06-29 | Sumitomo Pharma Co., Ltd. | Carboxylic acid compounds |
| CA2874800C (en) | 2012-07-13 | 2021-04-06 | Janssen R&D Ireland | Macrocyclic purines for the treatment of viral infections |
| KR102198128B1 (ko) | 2012-10-05 | 2021-01-05 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 및 추가 질환의 치료를 위한 아실아미노피리미딘 유도체 |
| NZ705589A (en) | 2012-10-10 | 2019-05-31 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
| AU2013346793B2 (en) | 2012-11-16 | 2018-03-08 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| KR102225233B1 (ko) * | 2013-02-21 | 2021-03-09 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
| MX366481B (es) | 2013-03-29 | 2019-07-09 | Janssen Sciences Ireland Uc | Deaza-purinonas macrociclicas para el tratamiento de infecciones virales. |
| MY188071A (en) | 2013-05-24 | 2021-11-16 | Janssen Sciences Ireland Uc | Pyridone derivatives for the treatment of viral infections and further diseases |
| CN109369643B (zh) | 2013-06-27 | 2021-05-18 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物 |
| EP3027624B1 (en) | 2013-07-30 | 2018-09-12 | Janssen Sciences Ireland UC | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
| JP6940916B2 (ja) | 2014-07-30 | 2021-09-29 | ゲノム プロテクション，インコーポレイテッド | フラジェリン組成物および使用 |
| MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| WO2016109002A2 (en) | 2014-10-16 | 2016-07-07 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
| SG11201802832UA (en) | 2015-10-07 | 2018-05-30 | Sumitomo Dainippon Pharma Co Ltd | Pyrimidine compound |
| WO2018002319A1 (en) | 2016-07-01 | 2018-01-04 | Janssen Sciences Ireland Uc | Dihydropyranopyrimidines for the treatment of viral infections |
| WO2018060317A1 (en) | 2016-09-29 | 2018-04-05 | Janssen Sciences Ireland Uc | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
| US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
| JP7071392B2 (ja) * | 2016-12-05 | 2022-05-18 | アプロス セラピューティクス， インコーポレイテッド | 酸性基を含有するピリミジン化合物 |
| FI3603619T3 (fi) | 2017-03-29 | 2025-09-25 | Sumitomo Pharma Co Ltd | Rokoteadjuvanttiformulaatio |
| AU2018391899A1 (en) | 2017-12-21 | 2020-07-02 | Sumitomo Pharma Co., Ltd. | Combination drug including TLR7 agonist |
| MX2020008746A (es) * | 2018-02-28 | 2020-09-28 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. |
| TW202415645A (zh) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| EP3802519A1 (en) | 2018-06-04 | 2021-04-14 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7 |
| MX2021000951A (es) | 2018-07-23 | 2021-06-23 | Sumitomo Pharma Co Ltd | Composición que contiene vacuna contra la influenza. |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1375162A (pt) | 1970-10-22 | 1974-11-27 | ||
| GB1546937A (en) | 1976-07-29 | 1979-05-31 | Beecham Group Ltd | 2,4-diaminopyrimidine derivatives |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
| DE3603577A1 (de) | 1986-02-06 | 1987-08-13 | Joachim K Prof Dr Seydel | Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit |
| JPH08165292A (ja) | 1993-10-07 | 1996-06-25 | Techno Res Kk | アデニン誘導体、その製造法及び用途 |
| US6110923A (en) | 1994-06-22 | 2000-08-29 | Biochem Pharma Inc. | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
| HUT77436A (hu) | 1994-10-05 | 1998-04-28 | Darwin Discovery Limited | Purin- és guaninszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására |
| KR19990044383A (ko) | 1996-07-03 | 1999-06-25 | 나가시마 카쭈시게, 노미야마 아키히코 | 신규 퓨린 유도체 |
| US6329381B1 (en) | 1997-11-28 | 2001-12-11 | Sumitomo Pharmaceuticals Company, Limited | Heterocyclic compounds |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| CA2333927A1 (en) | 1998-04-01 | 1999-10-07 | Dupont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
| ATE267175T1 (de) * | 1998-08-27 | 2004-06-15 | Sumitomo Pharma | Pyrimidin derivate |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| WO2001007027A2 (en) | 1999-07-22 | 2001-02-01 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives for the treatment of viral diseases |
| US20020128264A1 (en) | 2000-07-07 | 2002-09-12 | Taylor Eve M. | Methods for treatment of conditions affected by activity of multidrug transporters |
| ATE404561T1 (de) | 2001-04-17 | 2008-08-15 | Dainippon Sumitomo Pharma Co | Neue adeninderivate |
| EP1459727B1 (en) * | 2001-11-22 | 2010-06-09 | Japan Science and Technology Agency | Nonhuman model animal unresponsive to immunopotentiating synthetic compound |
| US7115373B2 (en) | 2002-06-27 | 2006-10-03 | Genox Research, Inc. | Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene |
| TWI349671B (en) | 2002-09-27 | 2011-10-01 | Dainippon Sumitomo Pharma Co | Novel adenine derivative and its use |
| EA200600069A1 (ru) | 2003-06-20 | 2006-08-25 | Коли Фармасьютикал Гмбх | Низкомолекулярные антагонисты toll-подобных рецепторов (tlr) |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| CN1845745B (zh) * | 2003-09-05 | 2011-11-02 | 安那迪斯药品股份有限公司 | Tlr7配体及其前药在制备用于治疗丙型肝炎病毒感染的药物中的用途 |
| ES2342069T4 (es) | 2003-09-05 | 2011-01-26 | Anadys Pharmaceuticals, Inc. | Ligandos de tlr7 para el tratamiento de la hepatitis c. |
| JPWO2005092892A1 (ja) | 2004-03-26 | 2008-02-14 | 大日本住友製薬株式会社 | ８−オキソアデニン化合物 |
| TWI392678B (zh) | 2004-03-26 | 2013-04-11 | Dainippon Sumitomo Pharma Co | ９-取代-８-氧基腺嘌呤化合物 |
| KR100700676B1 (ko) | 2005-06-24 | 2007-03-28 | (주) 비엔씨바이오팜 | 6―（4―치환된―아닐리노）피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물 |
| EP1931642A4 (en) | 2005-09-15 | 2011-06-01 | Orchid Res Lab Ltd | NEW PYRIMIDINE CARBOXAMIDES |
| JPWO2007034817A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| KR20090024270A (ko) | 2006-06-30 | 2009-03-06 | 아스트라제네카 아베 | 암 치료에 유용한 피리미딘 유도체 |
| CL2007002231A1 (es) | 2006-08-02 | 2008-04-11 | Basf Ag | Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico. |
| US20100056468A1 (en) | 2007-01-08 | 2010-03-04 | University Health Network | Pyrimidine Derivatives As Anticancer Agents |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| US8044056B2 (en) | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
| ES2452965T3 (es) | 2007-09-05 | 2014-04-03 | Rigel Pharmaceuticals, Inc. | Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina |
| PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
-
2010
- 2010-05-20 JP JP2012511356A patent/JP5913093B2/ja active Active
- 2010-05-20 CA CA2760766A patent/CA2760766A1/en not_active Abandoned
- 2010-05-20 WO PCT/GB2010/050825 patent/WO2010133885A1/en not_active Ceased
- 2010-05-20 AU AU2010250923A patent/AU2010250923A1/en not_active Abandoned
- 2010-05-20 BR BRPI1010937A patent/BRPI1010937A2/pt not_active IP Right Cessation
- 2010-05-20 EA EA201101650A patent/EA201101650A1/ru unknown
- 2010-05-20 UY UY0001032648A patent/UY32648A/es not_active Application Discontinuation
- 2010-05-20 EP EP10721195.5A patent/EP2432768B1/en active Active
- 2010-05-20 US US13/321,407 patent/US20120122867A1/en not_active Abandoned
- 2010-05-20 CN CN2010800338249A patent/CN102482233A/zh active Pending
- 2010-05-20 KR KR1020117030498A patent/KR20120030436A/ko not_active Withdrawn
- 2010-05-20 SG SG2011078433A patent/SG175796A1/en unknown
- 2010-05-20 MX MX2011012337A patent/MX2011012337A/es not_active Application Discontinuation
- 2010-05-21 TW TW099116416A patent/TW201100083A/zh unknown
- 2010-05-21 AR ARP100101776A patent/AR078045A1/es unknown
-
2011
- 2011-11-10 IL IL216283A patent/IL216283A0/en unknown
- 2011-11-21 CU CU20110212A patent/CU20110212A7/es unknown
- 2011-11-21 CR CR20110610A patent/CR20110610A/es unknown
- 2011-11-21 DO DO2011000361A patent/DOP2011000361A/es unknown
- 2011-11-21 EC EC2011011470A patent/ECSP11011470A/es unknown
- 2011-11-21 CL CL2011002942A patent/CL2011002942A1/es unknown
- 2011-11-30 CO CO11165091A patent/CO6470845A2/es not_active Application Discontinuation
- 2011-12-20 ZA ZA2011/09384A patent/ZA201109384B/en unknown
-
2014
- 2014-08-26 US US14/469,515 patent/US9533978B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010133885A1 (en) | 2010-11-25 |
| IL216283A0 (en) | 2012-01-31 |
| EP2432768B1 (en) | 2017-07-05 |
| EA201101650A1 (ru) | 2012-07-30 |
| CU20110212A7 (es) | 2012-03-15 |
| SG175796A1 (en) | 2011-12-29 |
| US20150080396A1 (en) | 2015-03-19 |
| KR20120030436A (ko) | 2012-03-28 |
| MX2011012337A (es) | 2011-12-08 |
| AU2010250923A1 (en) | 2011-11-17 |
| CL2011002942A1 (es) | 2012-04-13 |
| UY32648A (es) | 2010-12-31 |
| ECSP11011470A (es) | 2011-12-30 |
| US20120122867A1 (en) | 2012-05-17 |
| JP5913093B2 (ja) | 2016-04-27 |
| CO6470845A2 (es) | 2012-06-29 |
| DOP2011000361A (es) | 2011-12-15 |
| TW201100083A (en) | 2011-01-01 |
| CN102482233A (zh) | 2012-05-30 |
| US9533978B2 (en) | 2017-01-03 |
| JP2012527443A (ja) | 2012-11-08 |
| EP2432768A1 (en) | 2012-03-28 |
| ZA201109384B (en) | 2012-09-26 |
| CR20110610A (es) | 2012-01-09 |
| CA2760766A1 (en) | 2010-11-25 |
| AR078045A1 (es) | 2011-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1010937A2 (pt) | composto, uso de um composto, e, método para tratar câncer | |
| BRPI0908100A2 (pt) | produto combinação, uso de um composto, e, método de tratar câncer | |
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI0818426A2 (pt) | produto de combinação, uso de um produto de combinação, e, método para tratar câncer | |
| PT2434891T (pt) | Métodos para tratamento de cancro e afeções não neoplásicas | |
| BR112012003804A2 (pt) | Curativo para ferimentos, uso do mesmo, e, método para formar um curativo para ferimentos. | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| BR112012019936A2 (pt) | uso de um composto, método de preparação de um composto, método e composto | |
| BR112012002335A2 (pt) | pigmento composto e método para preparação do mesmo | |
| BRPI1010775A2 (pt) | composição, método para preparar uma composição, e, uso de uma composição. | |
| BRPI0906906A2 (pt) | Método para preparar um composto e composto | |
| BRPI0908252A2 (pt) | Processo para preparar um composto, e, uso de um composto | |
| BRPI1012978A2 (pt) | composição tópica, método para preparar a mesma, e, uso de um composto | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BRPI1010147A2 (pt) | processo para preparar um composto, uso de um processo e uso de um catalisador de irídio | |
| PT2340042E (pt) | Métodos e composições para o tratamento de cancro | |
| BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
| BRPI1009919A2 (pt) | combinações de pentamidina para tratamento de câncer. | |
| BRPI1010874A2 (pt) | composição para o tratamento de câncer de próstata | |
| BRPI1010933A2 (pt) | processo para a preparação de um pó, e, composto | |
| BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer | |
| BR112013014522A2 (pt) | anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| BR112012001030A2 (pt) | método para tratar a degeneração macular, e, uso de um composto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |